Nov 5th, 3:12 pm
PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38M
Nov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for 
JNJ 
MDT or even 
EW
Wells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
PEN Q3 top line beat of $111.8M vs consensus $102M, 33% yoy. Neuro grew 27%. Vascular grew 47%. Raised 2018 guide from $420-25M to $437-38MNov 6th, 9:15 am
PEN Check out this $5 billion innovator in catheter-based stroke treatment. Penumbra could be good tuck-in for JNJ MDT or even EWWells Fargo med-tech analyst Larry Biegelsen has been all over this since Q1 below $100. $180 PT. RBC Capital initiated last month with $174 PT.
PEN
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。